Timothy Dale Faw

A Novel Apolipoprotein E (apoE)-mimetic Pentapeptide to Improve Recovery in Acute Spinal Cord Injury · January 2021 - December 2021 Awarded by: Duke Institute for Brain Sciences · $75,000.00 Novel therapies that improve mobility after spinal cord injury (SCI) could lead to better quality of life and save billions of dollars in lifetime costs. Targeting the early inflammatory response to SCI is appealing, as it is the main cause of tissue damage after the initial injury. Apolipoprotein E (apoE) plays a critical role in mediating this neuroinflammation after nervous system damage. However, systemic delivery of the intact protein is ineffective as a therapeutic because it fails to cross the blood-brain barrier. As such, we have developed small, apoE-based peptides that mimic the function of the intact protein, cross the blood-brain barrier, and have few side effects. Here, we will test the hypothesis that early treatment with an apoE-mimetic peptide, CN-105, reduces inflammation, tissue damage, and improves recovery in a clinically relevant animal model of SCI. This peptide, developed at Duke, has received Investigational New Drug and Orphan Drug designations from the Food and Drug Administration, which will facilitate translation to early clinical trials.

Myelin Plasticity During Motor Learning After Spinal Cord Injury · August 2016 - February 2019 Principal Investigator · Awarded by: National Institutes of Health · $80,038.00

External Relationships

Oak Ridge Associated Universities

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.